What is the current Price Target for the Oramed Pharmaceuticals Inc. stock?

The average Oramed Pharmaceuticals Inc. target price is $3.25. This is 38.30% higher than the current stock price. 1 Analyst has issued a Oramed Pharmaceuticals Inc. price target 2025.

How high will the Oramed Pharmaceuticals Inc. stock rise?

No reliable answer can be given as to how high the Oramed Pharmaceuticals Inc. stock will rise. The performance of stocks, including the Oramed Pharmaceuticals Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Oramed Pharmaceuticals Inc. stock today?

The performance of Oramed Pharmaceuticals Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Oramed Pharmaceuticals Inc. stock fall?

The decline in Oramed Pharmaceuticals Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Oramed Pharmaceuticals Inc. Forecast, price target & analysts

$2.36

1.95% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US68403P2039

Symbol

ORMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Oramed Pharmaceuticals Inc. Target price 2024 - Analyst rating & recommendation

Oramed Pharmaceuticals Inc. Classifications & Recommendation:

Hold

100%

Oramed Pharmaceuticals Inc. Price Target

Target Price	$3.25
Price	$2.35
Potential	38.30% register free of charge
Number of Estimates	1

	1 Analyst has issued a Oramed Pharmaceuticals Inc. price target 2025. The average Oramed Pharmaceuticals Inc. target price is $3.25. This is 38.30% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 0 Analysts recommend Oramed Pharmaceuticals Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Oramed Pharmaceuticals Inc. stock has an average upside potential 2025 of 38.30% register free of charge . Most analysts recommend the Oramed Pharmaceuticals Inc. stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	0.14	0.31
	114.89%	121.43%
P/E		7.58

1 Analysts have issued a Oramed Pharmaceuticals Inc. forecast for earnings per share. The average Oramed Pharmaceuticals Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$0.14	114.89%
2024	$0.31 121.43% Unlock

Current	4.62	232.00%
2024	7.58 64.07% Unlock

Oramed Pharmaceuticals Inc....

Discover more stocks with a high price target

Valneva 196.57%

CureVac N.V. 194.05%

Plug Power Inc. 152.17%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now